Daisuke Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daisuke Kato has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Shino Muramatsu
Denka Co., Ltd. Gosen Site, Research & Development Division, Reagent R&D Department, 1-2-2 Minami-hon-cho, Gosen-shi, Niigata, 959-1695, Japan
5 shared publications - Atsuo Ueda
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan
4 shared publications - Hiromichi Suzuki
Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Japan
4 shared publications - Koji Nakamura
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan
4 shared publications - Shigeyuki Notake
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 3058558, Japan
4 shared publications - Yusaku Akashi
Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba
4 shared publications
Latest Publications
- Open Access
Development of an Immunochromatography Assay to Detect Marburg Virus and Ravn Virus
The recent outbreaks of Marburg virus disease (MVD) in Guinea, Ghana, Equatorial Guinea, and Tanzania, none of which had reported previous outbreaks, imply increasing risks of spillover of the causative viruses, Marburg virus (MARV) and Ravn virus (RAVV), from their natural host animals. These outbreaks have emphasized the need for the development of rapid diagnostic tests for this disease. Using monoclonal antibodies specific to the viral nucleoprotein, we developed an immunochromatography (IC) assay for the rapid diagnosis of MVD. The IC assay was found to be capable of detecting approximately 102−4 50% tissue culture infectious dose (TCID50)/test of MARV and RAVV in the infected culture supernatants. We further confirmed that the IC assay could detect the MARV and RAVV antigens in the serum samples from experimentally infected nonhuman primates. These results indicate that the IC assay to detect MARV can be a useful tool for the rapid point-of-care diagnosis of MVD.
Open AccessDevelopment of an Immunochromatography Assay to Detect Marburg Virus and Ravn Virus
The recent outbreaks of Marburg virus disease (MVD) in Guinea, Ghana, Equatorial Guinea, and Tanzania, none of which had reported previous outbreaks, imply increasing risks of spillover of the causative viruses, Marburg virus (MARV) and Ravn virus (RAVV), from their natural host animals. These outbreaks have emphasized the need for the development of rapid diagnostic tests for this disease. Using monoclonal antibodies specific to the viral nucleoprotein, we developed an immunochromatography (IC) assay for the rapid diagnosis of MVD. The IC assay was found to be capable of detecting approximately 102−4 50% tissue culture infectious dose (TCID50)/test of MARV and RAVV in the infected culture supernatants. We further confirmed that the IC assay could detect the MARV and RAVV antigens in the serum samples from experimentally infected nonhuman primates. These results indicate that the IC assay to detect MARV can be a useful tool for the rapid point-of-care diagnosis of MVD.
- Open Access
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Open AccessAnalytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant
- Open Access
- 7 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 840-843
A prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu+COVID19 Ag
- 7 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 840-843
Open AccessA prospective evaluation of diagnostic performance of a combo rapid antigen test QuickNavi-Flu+COVID19 Ag
- 10 November 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 248-251
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
- 10 November 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 248-251
Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 890-894
The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 890-894
Open AccessThe evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan